The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICLE 2022 | Current research on anti-CD38 CAR T-cell therapies
Tuna Mutis, MD, PhD, Amsterdam University Medical Center, Amsterdam, The Netherlands, gives an overview of his research on developing chimeric antigen receptor (CAR) T-cell therapies targeting CD38. As a result of the development of daratumumab, an anti-CD38 monoclonal antibody for patients with multiple myeloma, efforts to develop efficacious anti-CD3 CAR T-cell therapies are currently underway. Prof. Mutis additionally highlights B-cell maturation antigen (BCMA) as a novel target and dual targeting as a potential strategy to enhance cell therapies. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.
